You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD-19

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CNS Lymphoma Trial in Nanchang (Human CD19-CD22 Targeted T Cells Injection)

Recruiting
  • Central Nervous System Lymphoma
  • Human CD19-CD22 Targeted T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CD19 specific Chimeric Antigen Receptor T Cell
  • Columbus, Ohio
    Nationwide Children's Hospital
Mar 9, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

Diffuse Large B-cell Lymphoma Trial in Hangzhou, Ningbo (CD19-7×19 CAR-T combined with Tislelizumab)

Recruiting
  • Diffuse Large B-cell Lymphoma
  • CD19-7×19 CAR-T combined with Tislelizumab
  • Hangzhou, Zhejiang, China
  • +1 more
Dec 12, 2022

Acute Lymphoblastic Leukemia, Non Hodgkin Lymphoma Trial (CD19-UCART)

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • Non Hodgkin Lymphoma
  • CD19-UCART
  • (no location specified)
Jan 25, 2023

CD 19+ Acute Leukemia Trial in Seattle (T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC))

Active, not recruiting
  • CD 19+ Acute Leukemia
  • T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)
  • Seattle, Washington
    Seattle Children's Hospital
Mar 22, 2022

Relapsed and Refractory B-cell Lymphoma Trial (CD19 CAR-T and CD19 CAR-DC)

Not yet recruiting
  • Relapsed and Refractory B-cell Lymphoma
  • CD19 CAR-T and CD19 CAR-DC
  • (no location specified)
Oct 16, 2022

Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)

Completed
  • Acute Lymphoblastic Leukemia
  • CAR-NK-CD19 Cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Nov 24, 2022

CNS Lymphoma Trial in Duarte (procedure, biological, drug)

Recruiting
  • Central Nervous System Lymphoma
  • Aspiration
  • +10 more
  • Duarte, California
    City of Hope Medical Center
Dec 8, 2022

Non-hodgkin Lymphoma,B Cell Trial in Beijing (Autologous CD19-STAR-T cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non-hodgkin Lymphoma,B Cell
  • Autologous CD19-STAR-T cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2022

Lymphoma, B-Cell Trial in Langfang (CD19 and CD22 targeted CAR-T cells)

Not yet recruiting
  • Lymphoma, B-Cell
  • CD19 and CD22 targeted CAR-T cells
  • Langfang, Hebei, China
    Hebei Yanda Ludaopei Hospital
Dec 6, 2022

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (U-CAR-T Cells (LstCAR019))

Withdrawn
  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL
  • U-CAR-T Cells (LstCAR019)
  • Kunming, Yunnan, China
    Kunming Hope of Health Hospital
Nov 27, 2022

B-cell Acute Lymphoblastic Leukemia, B-ALL Trial in Kunming (UCAR-T Cells)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • B-ALL
  • UCAR-T Cells
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Dec 7, 2022

Graft Vs Host Disease, Graft-versus-host-disease, Acute Myeloid Leukemia Trial (CliniMACS® device)

Not yet recruiting
  • Graft Vs Host Disease
  • +5 more
  • CliniMACS® device
  • (no location specified)
Jul 20, 2023

B-Cell Leukemia, B-Cell Lymphoma, B-cell Tumors Trial in Kunming (Anti-CD19 Autologous CAR-T Cell Infusion)

Recruiting
  • B-Cell Leukemia
  • +2 more
  • Anti-CD19 Autologous CAR-T Cell Infusion
  • Kunming, Yunnan, China
    920th Hospital of Joint Logistics Support Force of People's Libe
Jul 9, 2023

Non Hodgkin's Lymphoma Trial in Beijing (Allogenic CD19-CAR-?dT cell, Fludarabine, Cyclophosphamide)

Recruiting
  • Non Hodgkin's Lymphoma
  • Allogenic CD19-CAR-γδT cell
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Jan 31, 2023

Diffuse Large B Cell Lymphoma Trial (anti-CD19 CAR NK cells)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • anti-CD19 CAR NK cells
  • (no location specified)
Dec 21, 2022

B-cell Acute Lymphoblastic Leukemia Trial in Nanchang (Human CD19 Targeted DASH CAR-T Cells Injection)

Recruiting
  • B-cell Acute Lymphoblastic Leukemia
  • Human CD19 Targeted DASH CAR-T Cells Injection
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Dec 13, 2022

B-cell Non Hodgkin Lymphoma Trial in Xuzhou (regimen with BTK inhibitor +Anti-CD19 CAR T cells)

Recruiting
  • B-cell Non Hodgkin Lymphoma
  • regimen with BTK inhibitor +Anti-CD19 CAR T cells
  • Xuzhou, Jiangsu, China
    The Affiliated Hospital of Xuzhou Medical University
Feb 23, 2023

Systemic Lupus Erythematosus (SLE) Trial (BRL-301)

Not yet recruiting
  • Systemic Lupus Erythematosus (SLE)
  • BRL-301
  • (no location specified)
Aug 13, 2023

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Acute Lymphocytic Leukemia Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor (CAR) T Cells)

Recruiting
  • Acute Lymphocytic Leukemia
  • CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
  • Tianjin, Tianjin, China
    Hematology Hospital, Chinese Academy of Medical Sciences
Feb 5, 2023

B-cell Lymphoma Trial in Hangzhou (PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells)

Active, not recruiting
  • B-cell Lymphoma
  • PD1 specific integrated anti-CD19 Chimeric Antigen Receptor T Cells
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University School of Med
Sep 28, 2022